Esther I. van Vliet

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate

Esther I. van Vliet, Casper H.J. van Eijck, Ronald R. de Krijger et al. · Journal of Nuclear Medicine · 2015 · 120 citations · Full text

Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy

E. van Schaik, Esther I. van Vliet, Richard A. Feelders et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 98 citations

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen et al. · Best Practice & Research Clinical Gastroenterology · 2012 · 75 citations

Signal Transduction, Medicine, Neuropeptide Receptor +5

Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate

Esther I. van Vliet, Eric P. Krenning, Jaap J.M. Teunissen et al. · Journal of Nuclear Medicine · 2013 · 45 citations · Full text

Tumor Response Assessment to Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

Esther I. van Vliet, John J. Hermans, Maria A. de Ridder et al. · Journal of Nuclear Medicine · 2012 · 20 citations · Full text